drugset / Trial / NCT02217410
CCFZ533X2201 - PoC Study in de Novo Renal Transplantation
RandomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this study was to investigate the safety, tolerability, pharmacokinetics (PK) and potential for CFZ533 to replace calcineurin inhibitors (CNI), while providing a similar rate of acute rejection prophylaxis and renal function in a de novo renal transplant population receiving an allograft from standard criteria donors.
Timeline
- Start
- 2015-02-05
- Primary completion
- 2017-11-29
- Completion
- 2017-11-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tacrolimus | Small molecule | — | — |
| Subject | iscalimab | Monoclonal antibody | — | — |
| Background | Mycophenolate Mofetil | Small molecule | — | — |
Indications
No indication recorded.